SAN DIEGO – After reporting upbeat data from the first part of an experiment with omaveloxolone for Friedreich's ataxia (FA), Reata Pharmaceuticals Inc. has adjusted the second part for better chances of continued victory, vice president of strategy Vineet Jindal told BioWorld at the BIO International Convention.